Free tool
FAERS Monitor: Daliresp
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022522 or its brand name (Daliresp, Roflumilast). Reports on generic versions are filed under their own applications.
Reports
6,156
Serious
4,118
67% of reports
Hospitalization
2,056
Death reported
958
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,062
- death743
- chronic obstructive pulmonary disease669
- diarrhoea539
- pneumonia470
- nausea461
- weight decreased443
- cough366
- headache359
- drug ineffective322
- off label use317
- dizziness300
- asthma299
- insomnia298
- malaise288
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 5 |
| 2011 | 77 |
| 2012 | 676 |
| 2013 | 493 |
| 2014 | 460 |
| 2015 | 396 |
| 2016 | 427 |
| 2017 | 325 |
| 2018 | 329 |
| 2019 | 389 |
| 2020 | 360 |
| 2021 | 336 |
| 2022 | 341 |
| 2023 | 448 |
| 2024 | 341 |
| 2025 | 391 |
| 2026 | 362 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,003 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic obstructive pulmonary diseaseSignal | 669 | 44.4 | 41.3 | 28,018 |
| asthmaSignal | 299 | 9.1 | 8.1 | 2,142 |
| dyspnoeaSignal | 1,062 | 6.4 | 6.1 | 4,979 |
| weight decreasedSignal | 443 | 5.4 | 5.0 | 1,615 |
| pneumoniaSignal | 470 | 5.0 | 4.6 | 1,506 |
| coughSignal | 366 | 4.5 | 4.0 | 992 |
| insomniaSignal | 298 | 3.8 | 3.4 | 626 |
| deathSignal | 743 | 2.9 | 2.8 | 995 |
| diarrhoeaSignal | 539 | 2.9 | 2.6 | 667 |
| malaiseSignal | 288 | 2.2 | 2.0 | 202 |
| dizzinessSignal | 300 | 2.1 | 1.8 | 165 |
| nausea | 461 | 2.0 | 1.8 | 235 |
| headache | 359 | 2.0 | 1.8 | 172 |
| off label use | 317 | 1.2 | 1.1 | 15 |
| drug ineffective | 322 | 0.8 | 0.8 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.